India’s first indigenous mRNA vaccine candidate receives approval to initiate Phase 1 and 2 human clinical trials

India’s first indigenous mRNA vaccine candidate receives approval to initiate Phase 1 and 2 human clinical trials

India’s first indigenous mRNA vaccine candidate has received approval from Indian Drug regulators to initiate Phase one and two human clinical trials. The novel mRNA vaccine candidate, HGCO19 has been developed by Gennova, Pune and supported with seed grant under the Ind-CEPI mission of the Department of Biotechnology. The mRNA vaccines do not use the conventional model to produce immune response. Instead, they carry the molecular instructions to make the protein in the body through a synthetic RNA of the virus. mRNA-based vaccines are scientifically the ideal choice to address a pandemic because of their rapid developmental timeline. The mRNA vaccine is considered safe as is non-infectious, non-integrating in nature, and degraded by standard cellular mechanisms.

also read First training programme of Hindustan Aeronautics Limited -IISc Skill Development Centre launched

also read AYUSH Export Promotion Council to be set up